Tumor vaccines for the management of prostate cancer

• Authors: D.G. McNeel , M.L. Disis
• Languages of publication: EN

Abstracts

EN

Prostate cancer is a significant health problem and one of the leading causes of cancer-related death among men. Given the typically long natural history of the disease, there is considerable interest in developing new therapies to treat or prevent metastatic disease, and cancer vaccines are a particularly attractive immune-based approach. Early clinical studies using non-specific immunomodulatory treatments have met with limited success, but also suggest that improved immunologic approaches might be useful in treating human prostate cancer. Over the last decade, the identification of immune cells responsible for actual destruction of prostate tissue and advances in immunologic and molecular techniques have led to a variety of vaccination approaches that are currently being evaluated in human clinical trials. The present article discusses the rationale in animal models for particular immunization strategies and describes the vaccines currently being used in patients with prostate cancer. The ongoing identification of tumor antigens and proteins involved in prostate cancer progression and the development of better immunologic animal models suggest a hopeful future for the design of effective prostate cancer vaccines.

Keywords

EN

IMMUNOTHERAPY; PROSTATE CANCER; TUMOR VACCINE

Discipline

• IMMUNOLOGY: IMMUNOLOGY

• Publisher: Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
• Journal: Archivum Immunologiae et Therapiae Experimentalis
• Year: 2000
• Volume: 48
• Issue: 2
• Pages: 85-93

Contributors

author

D.G. McNeel

author

M.L. Disis

• Document Type: REVIEW
• Publication order reference: D.G. McNeel, Division of Medical Oncology, University of Washington, Seattle, WA, USA